Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

LSE Group full-year profit beats analyst estimates

(Sharecast News) - The London Stock Exchange posted in line full-year top-line growth, but its profit beat analysts' estimates. "Key highlights for the year include material enhancements to the Workspace platform; the availability of more of our leading datasets across cloud-based platforms, meeting our customers where they want to work; and continued significant progress across products and geographies for Post Trade," LSE boss David Schwimmer said.

"In addition, we have been a driving force behind reforms that secure London's position as a leading global venue for capital raising. We also reached an important milestone in our partnership with Microsoft, with the first products now generally available for customers, and a strong pipeline for 2025."

Reported total income, excluding recoveries, was ahead by 6.1% to reach approximately £8.49bn and by 5.7% to £8.85bn once recoveries are included.

In organic terms and at constant currencies, revenues were up by 7.7%.

On an adjusted basis, earnings before interest, taxes, depreciation and amortisation jumped 9.8% to about £4.15bn, for a 12.2% rise in earnings per share to 363.5p (UBS: 354.5p).

Income in the key Data & Analytics unit was up by 4.5% for the year, or roughly twice the pace anticipated by UBS, and by 4.8% over the last three months of 2024.

Organic Annual Subscription Values meanwhile rose by 6.3%

Looking ahead, LSE Group guided towards organic total income growth at constant currencies of 6.5-7.5% once recoveries are excluded.

One week before LSE's latest results, UBS analyst Michael Werner had written to clients that: "LSEG's shares are trading at 28.5x forward consensus earnings. At these valuation levels the market is, in our view, pricing in a revenue growth outlook of 6% per annum, c.150bp below our expectations."

Also at constant FX, EBITDA margins were seen strengthening by 50-100 basis points.

Equity free cash flow was pegged to rise by at least £2.4bn.

A further £500m of share buybacks were expected to be concluded by July 2025 and the final dividend was raised by 12.2% to 89.0p.

-- More to follow --

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.